Zvonko Milicevic

List of Publications by Year
in descending order

35 papers	2,729 citations	331670 21 h-index	361022 35 g-index
36 all docs	36 docs citations	36 times ranked	2332 citing authors

#	Article	IF	Citations
1	Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet, The, 2018, 392, 2180-2193.	13.7	528
2	Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial. Diabetes Care, 2009, 32, 381-386.	8.6	320
3	Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care, 2014, 37, 2149-2158.	8.6	236
4	Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 370-381.	11.4	185
5	Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet, The, 2015, 385, 2057-2066.	13.7	180
6	Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 388-396.	3.6	129
7	Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Diabetes, Obesity and Metabolism, 2020, 22, 938-946.	4.4	126
8	Natural History of Cardiovascular Disease in Patients With Diabetes. Diabetes Care, 2008, 31, S155-S160.	8.6	118
9	Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2‰years in metformin‐treated patients with type 2 diabetes (<scp>AWARD</scp>‐5): a randomized, phase <scp>III</scp> study. Diabetes, Obesity and Metabolism, 2015, 17, 849-858.	4.4	108
10	Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (<scp>AWARD</scp>‐9). Diabetes, Obesity and Metabolism, 2017, 19, 1024-1031.	4.4	98
11	Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 418-429.	11.4	95
12	Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care, 2021, 44, 765-773.	8.6	91
13	Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia. Diabetes Care, 2011, 34, 1511-1513.	8.6	72
14	Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: A multinational, 24-week, randomized, open-label, parallel-group comparison. Clinical Therapeutics, 2007, 29, 2349-2364.	2.5	61
15	Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A <i>post‐hoc</i> analysis of the AWARD‐2, ‐4 and ‐5 Trials. Diabetes, Obesity and Metabolism, 2018, 20, 1490-1498.	4.4	40
16	Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonist dulaglutide in combination with prandial insulin lispro: an <scp>AWARD</scp>‐4 substudy. Diabetes, Obesity and Metabolism, 2016, 18, 999-1005.	4.4	37
17	Comparative efficacy of preprandial or postprandial humalog® mix75/25™ versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. Clinical Therapeutics, 2002, 24, 73-86.	2.5	32
18	Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D). Journal of Diabetes and Its Complications, 2005, 19, 80-87.	2.3	28

#	Article	IF	Citations
19	Functionality and acceptability of a new electronic insulin injection pen with a memory feature. Current Medical Research and Opinion, 2006, 22, 315-325.	1.9	28
20	Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin. Diabetes, Obesity and Metabolism, 2019, 21, 2048-2057.	4.4	26
21	Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?. Diabetes Research and Clinical Practice, 2003, 62, 187-195.	2.8	24
22	Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide. Diabetes, Obesity and Metabolism, 2016, 18, 533-536.	4.4	23
23	Glycemic control with Humalog® Mix25™ in type 2 diabetes inadequately controlled with glyburide. Clinical Therapeutics, 2001, 23, 1732-1744.	2.5	21
24	Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. Diabetes Care, 2017, 40, 647-654.	8.6	20
25	Differential effects of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide and metformin on pancreatic β‐cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 834-839.	4.4	16
26	Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities. Israel Medical Association Journal, 2003, 5, 801-6.	0.1	15
27	Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. Diabetic Medicine, 2001, 18, 562-566.	2.3	12
28	Effect of Two Starting Insulin Regimens in Patients with Type II Diabetes not Controlled on a Combination of Oral Antihyperglycemic Medications. Experimental and Clinical Endocrinology and Diabetes, 2009, 117, 223-229.	1.2	12
29	Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. Expert Opinion on Investigational Drugs, 2012, 21, 1463-1474.	4.1	12
30	Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). Clinical Therapeutics, 2017, 39, 2284-2295.	2.5	11
31	Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial. Diabetes, Obesity and Metabolism, 2019, 21, 2570-2575.	4.4	11
32	P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation. Collegium Antropologicum, 2013, 37, 491-8.	0.2	11
33	β-Cell Secretory Function and CD25 + Lymphocyte Subsets In the Early Stage of Type 1 Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2004, 112, 181-186.	1.2	1
34	How to interpret results of the HEART2D trial?. Diabetes Research and Clinical Practice, 2009, 86, S53-S56.	2.8	1
35	Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post‐hoc analysis of the AWARD‐2, ‐4 and ‐5 trials". Diabetes, Obesity and Metabolism, 2018, 20, 2319-2320.	4.4	0